GEN-001

DRUG4 trials

Conditions

Biliary Tract CancerGastric CancerGastroesophageal Junction AdenocarcinomaLocally Advanced Rectal CancerNon Small Cell Lung CancerSolid TumorSquamous Cell Carcinoma of Head and NeckUrothelial Carcinoma

Phase 1

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

CompletedNCT04601402

Genome & CompanyNon Small Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma of Head and Neck +1

Start: 2020-10-26End: 2023-01-11Updated: 2023-08-08

Phase 2

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

CompletedNCT05419362

Genome & CompanyGastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2022-04-07End: 2024-08-26Updated: 2025-12-16

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

TerminatedNCT05998447

Genome & CompanyBiliary Tract Cancer

Start: 2023-09-18End: 2024-11-26Updated: 2025-12-16

Unknown Phase

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

NCT05079503

Korean Cancer Study GroupLocally Advanced Rectal Cancer

Start: 2021-12-15End: 2024-01-30Target: 40Updated: 2021-10-15

Related Papers

Phase II study of GEN-001 in combination with avelumab in patients with PD-L1–positive locally advanced, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) who have progressed after second-line (2L) and beyond (GEN001-201 study).